Panel Discussion: Assessing the Pros & Cons of Muscarinic PAMs vs. Agonists for Side Effect Alleviation & Efficacy Across Symptom Domains
Time: 4:30 pm
day: Day One PM
Details:
- What are the main advantages and disadvantages of preclinically developing and clinically investigating a muscarinic receptor agonist compared to a PAM, and how are the disadvantages currently being addressed?
- Evaluating differences in efficacy signals: are there specific indications where one approach might be more beneficial than the other?
- What are the differences in side effect profiles experienced with PAMs vs agonists?
